Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWomen taking Mounjaro alongside an oral contraceptive pill need to take an extra precaution: for the first four weeks of treatment, and for four weeks after every dose increase, a non-oral method of contraception — such as condoms — should be added. This is because Mounjaro slows gastric emptying, which can reduce how much of the pill is absorbed. The MHRA and NHS England's guidance on weight-management injections both flag this specifically for tirzepatide (the medicine in Mounjaro), and your prescriber will discuss it with you before treatment begins. Mounjaro is a prescription-only medicine; clinical assessment determines whether it is right for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide, the active ingredient in Mounjaro, is a dual GIP and GLP-1 receptor agonist. One of its actions is to slow gastric emptying, the rate at which the stomach passes its contents into the small intestine. For most purposes this is a feature, not a flaw; it is part of how the medicine reduces appetite. But it matters for oral medicines whose absorption depends on moving through the gut efficiently.
The contraceptive pill is absorbed through the intestinal wall. If gastric emptying is slowed, the window and extent of that absorption can change. NHS England's guidance is explicit on this point: women using oral contraceptives alongside Mounjaro should use an additional barrier method for four weeks from starting treatment and for four weeks after each dose step up. The NHS tirzepatide medicines page echoes this, noting that the pill may be less effective during these periods.
The precaution applies each time the dose increases, so at the 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg transitions as well as at the start. Outside those four-week windows, current evidence on whether Mounjaro affects the contraceptive pill does not indicate a sustained effect on pill absorption, but your prescriber is the right person to confirm what applies to your specific regimen.
Practically, this means deciding which non-oral method you will use before you take your first Mounjaro dose. Condoms are the most straightforward choice for most women. A contraceptive patch, injection, implant, or hormonal IUS are all methods that bypass oral absorption entirely and are unaffected by gastric emptying, how Mounjaro interacts with the implant is a separate question worth reading if that is the route you prefer.
It is worth keeping a note of the date of each dose change. When your pen moves to the next strength, the four-week additional-contraception clock restarts from that injection day. Some women find it easiest to set a reminder on their phone alongside the weekly injection reminder, the same way you might put a sticky note on the fridge door next to where you store the pen.
If you take the pill for reasons beyond contraception (managing endometriosis or PCOS, for example) tell your prescriber this during your consultation. The interaction consideration does not disappear in that context, and your prescriber may want to involve your GP or specialist in the conversation.
Mounjaro is not recommended during pregnancy, while breastfeeding, or for anyone actively trying to conceive. This is a licensing position, not a precautionary preference: the medicine has not been studied in these groups, and the safety data needed to support its use simply do not exist. If you are planning a pregnancy, you should discuss stopping Mounjaro with your prescriber in good time, the MHRA advises a wash-out period before conception; your prescriber will guide you on what that looks like for you personally.
For a fuller picture of what the evidence says and where the gaps are, the fertility and pregnancy considerations page covers the topic in more detail. The short answer: use reliable contraception consistently throughout Mounjaro treatment, and plan any decision to stop in conversation with your clinical team rather than unilaterally.
More broadly, Mounjaro and contraception is a topic that spans several methods, the pill is the one that requires the most active management, but it is not the only one worth understanding before you start.
Questions about the contraceptive pill and Mounjaro are ones our prescribers hear regularly. A good consultation is the place to surface them, not an afterthought. When you consult with nume (with our clinical team) a GPhC-registered Independent Prescriber reads your answers personally the same day. They will ask about your current medicines, including contraception, and factor them into their decision.
If you are already on Mounjaro and have questions about a recent dose change, or want to revisit your contraceptive plan, our aftercare team is available seven days a week. You can also read the broader guidance on Mounjaro and oral contraceptives for more context on how this interaction is understood clinically.
Mounjaro is a prescription-only medicine. Whether it is clinically appropriate for you, and how to manage your contraception alongside it, is a decision made with a prescriber, not a one-size-fits-all protocol.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.